Antibiotic Research Stalling In Conversion Of Target Into New Drug
Executive Summary
Translating validated targets into clinical candidates is the major hurdle in discovering new antibiotics to combat resistance, Lilly VP-Scientific Affairs Gail Cassell, PhD, suggested in a presentation to FDA's Center for Drug Evaluation & Research Jan. 7
You may also be interested in...
Antibiotics Should Be One Step On FDA’s “Critical Path,” Lilly VP Says
Antibiotic development is an ideal FDA "Critical Path" opportunity due to the lack of antitrust concerns surrounding the therapeutic category, Lilly VP-Scientific Affairs Gail Cassell, PhD, told the FDA Science Board Advisory Committee April 22
Antibiotics Should Be One Step On FDA’s “Critical Path,” Lilly VP Says
Antibiotic development is an ideal FDA "Critical Path" opportunity due to the lack of antitrust concerns surrounding the therapeutic category, Lilly VP-Scientific Affairs Gail Cassell, PhD, told the FDA Science Board Advisory Committee April 22
Antibiotic Trial Without Comparator Would Lower R&D Cost, Wyeth Exec Says
Antibiotic trials without comparator drug arms would lower development costs, Wyeth Antibacterial Research Director Steven Projan, PhD, suggested